295 related articles for article (PubMed ID: 31099673)
21. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
[TBL] [Abstract][Full Text] [Related]
22. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
23. Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: A meta-analysis.
Pereira Mestre R; Treglia G; Ferrari M; Pascale M; Mazzara C; Azinwi NC; Llado' A; Stathis A; Giovanella L; Roggero E
Eur J Clin Invest; 2019 Mar; 49(3):e13063. PubMed ID: 30580449
[TBL] [Abstract][Full Text] [Related]
24. Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer.
Meyer AR; Joice GA; Allaf ME; Rowe SP; Gorin MA
Curr Opin Urol; 2018 Nov; 28(6):493-498. PubMed ID: 30188333
[TBL] [Abstract][Full Text] [Related]
25. PSMA: a game changer in the diagnosis and treatment of advanced prostate cancer.
Parsi M; Desai MH; Desai D; Singhal S; Khandwala PM; Potdar RR
Med Oncol; 2021 Jun; 38(8):89. PubMed ID: 34181109
[TBL] [Abstract][Full Text] [Related]
26. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
[TBL] [Abstract][Full Text] [Related]
27. Radionuclide Therapy of Metastatic Prostate Cancer.
Kratochwil C; Haberkorn U; Giesel FL
Semin Nucl Med; 2019 Jul; 49(4):313-325. PubMed ID: 31227054
[TBL] [Abstract][Full Text] [Related]
28. Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy.
Eiber M; Fendler WP; Rowe SP; Calais J; Hofman MS; Maurer T; Schwarzenboeck SM; Kratowchil C; Herrmann K; Giesel FL
J Nucl Med; 2017 Sep; 58(Suppl 2):67S-76S. PubMed ID: 28864615
[TBL] [Abstract][Full Text] [Related]
29. Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning.
Gupta SK; Watson T; Denham J; Shakespeare TP; Rutherford N; McLeod N; Picton K; Ainsworth P; Bonaventura T; Martin JM
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(3):701-709. PubMed ID: 29280465
[TBL] [Abstract][Full Text] [Related]
30. Advances in prostate-specific membrane antigen PET of prostate cancer.
Bouchelouche K; Choyke PL
Curr Opin Oncol; 2018 May; 30(3):189-196. PubMed ID: 29465429
[TBL] [Abstract][Full Text] [Related]
31. Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA.
Psimadas D; Valotassiou V; Alexiou S; Tsougos I; Georgoulias P
Cancer Invest; 2018 Feb; 36(2):118-128. PubMed ID: 29393702
[TBL] [Abstract][Full Text] [Related]
32. Utility of
Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
[TBL] [Abstract][Full Text] [Related]
33. New aspects of molecular imaging in prostate cancer.
Ceci F; Castellucci P; Cerci JJ; Fanti S
Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
Arsenault F; Beauregard JM; Pouliot F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
[TBL] [Abstract][Full Text] [Related]
35. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
Veliev EI; Tomilov AA; Goncharuk DA; Bogdanov AB; Golubtsova EN
Urologiia; 2018 Jul; (3):105-110. PubMed ID: 30035428
[TBL] [Abstract][Full Text] [Related]
36. Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.
Miyahira AK; Pienta KJ; Morris MJ; Bander NH; Baum RP; Fendler WP; Goeckeler W; Gorin MA; Hennekes H; Pomper MG; Sartor O; Tagawa ST; Williams S; Soule HR
Prostate; 2018 Aug; 78(11):775-789. PubMed ID: 29717499
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse.
Su HC; Zhu Y; Ling GW; Hu SL; Xu XP; Dai B; Ye DW
Asian J Androl; 2017; 19(3):267-271. PubMed ID: 27976632
[TBL] [Abstract][Full Text] [Related]
38. [PSMA-based theranostics for prostate cancer : From imaging to treatment].
Ilhan H; la Fougère C; Krause BJ
Urologe A; 2020 May; 59(5):617-625. PubMed ID: 32377764
[TBL] [Abstract][Full Text] [Related]
39. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
[TBL] [Abstract][Full Text] [Related]
40. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer.
Foss CA; Mease RC; Fan H; Wang Y; Ravert HT; Dannals RF; Olszewski RT; Heston WD; Kozikowski AP; Pomper MG
Clin Cancer Res; 2005 Jun; 11(11):4022-8. PubMed ID: 15930336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
